Society guideline links: Hereditary breast and ovarian cancer

Introduction — This topic includes links to society and government-sponsored guidelines from selected countries and regions around the world. We will update these links periodically; newer versions of some guidelines may be available on each society's website. Some societies may require users to log in to access their guidelines.

The recommendations in the following guidelines may vary from those that appear in UpToDate topic reviews. Readers who are looking for UpToDate topic reviews should use the UpToDate search box to find the relevant content.

Links to related guidelines are provided separately:

●(See "Society guideline links: Breast cancer".)

●(See "Society guideline links: Screening for breast cancer".)

●(See "Society guideline links: Breast surgery".)

●(See "Society guideline links: Ovarian, fallopian tube, and peritoneal cancer".)

●(See "Society guideline links: Screening for ovarian cancer".)

●(See "Society guideline links: Evaluation of breast problems".)

Canada

●Ontario Health (Cancer Care Ontario [CCO]): Guideline on risk reduction strategies for BRCA1/2 hereditary ovarian cancer syndromes (2020)

●Society of Obstetricians and Gynaecologists of Canada (SOGC): Clinical practice guideline for gynaecologic management of hereditary breast and ovarian cancer (2018)

United States

●American College of Medical Genetics and Genomics (ACMG): A clinical practice resource for management of individuals with germline variants in PALB2 (2021)

●American Society of Clinical Oncology (ASCO): Management of hereditary breast cancer, rapid recommendation update (2021)

•ASCO: Adjuvant PARP inhibitors in patients with high-risk early-stage HER2-negative breast cancer and germline BRCA mutations – Hereditary breast cancer guideline, rapid recommendation update (2021)

•ASCO, American Society for Radiation Oncology (ASTRO), and Society of Surgical Oncology (SSO): Management of hereditary breast cancer – Guideline (2020)

●American College of Obstetricians and Gynecologists (ACOG): Committee opinion on cascade testing – Testing women for known hereditary genetic mutations associated with cancer (2018, reaffirmed 2020)

●ACOG: Committee opinion on hereditary cancer syndromes and risk assessment (2019)

●American Society of Breast Surgeons (ASBrS): Consensus guideline on genetic testing for hereditary breast cancer (2019)

●US Preventive Services Task Force (USPSTF): Final recommendation statement on BRCA-related cancer – Risk assessment, genetic counseling, and genetic testing (2019)

●ACOG and Society of Gynecologic Oncology (SGO): Practice bulletin on hereditary breast and ovarian cancer syndrome (2017)

●SGO: White paper on multi-disciplinary summit on genetics services for women with gynecologic cancers (2017)

●SGO: Statement on risk assessment for inherited gynecologic cancer predispositions (2015)

●SGO: Clinical practice statement on genetic testing for ovarian cancer (2014)

●SGO: Clinical practice statement on next generation cancer gene panels versus gene by gene testing (2014)

●SGO: Position statement on genetic testing for gynecologic cancer (2014)

Europe

●European Society for Medical Oncology (ESMO): Clinical practice guideline on risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes (2022)

United Kingdom

●National Institute for Health and Care Excellence (NICE): Clinical guideline on familial breast cancer – Classification, care, and managing breast cancer and related risks in people with a family history of breast cancer (2013, updated 2023)

●NICE: Quality standard on breast cancer (2011, updated 2016)

India

●Indian Council of Medical Research (ICMR): Consensus document for management of breast cancer (2016)

Australia–New Zealand

●Royal Australian College of General Practitioners (RACGP): Genomics in general practice – Familial breast and ovarian cancer (2022)

●Cancer Australia: Position statement on genetic testing for women diagnosed with ovarian cancer (2017)

●Cancer Australia: Recommendations for the management of early breast cancer in women with an identified BRCA1 or BRCA2 gene mutation or at high risk of a gene mutation (2014)